Women’s health is finally getting the treatment it deserves. Historically overlooked, downplayed, and neglected, investors have spotted the largely untapped opportunity the sector presents. Venture capital investment in the women’s health sector has surged by 314% over the past five years, and despite the recent slowdown in startup funding, mid-year data shows the sector is on track for another record-breaking year.
While women spend 25% more time in poor health compared to men, the prognosis is incredibly promising. According to the World Economic Forum’s Global Gender Gap report, the health gap has closed by 96% since tracking began in 2006—and as research and innovation in the space continues, the coming years promise further improvement, providing women the world over with tools and treatments to help them live longer, happier, and more comfortable lives.
2025’s top women’s health trends
As interest and investment in the women’s health space grows, this will drive marked improvements and widespread innovation in the sector, with a number of key trends beginning to emerge.
1. Predictive and preventative care
By 2030, an estimated 1.2 billion women will be of menopausal or postmenopausal age. However, rather than waiting for symptoms to appear, there is a growing trend towards proactive management for women in their 30s and early 40s.
Research shows that making targeted lifestyle adjustments—eating a balanced diet, exercising regularly, and taking care of your mental health—combined with the right supplements can significantly delay, manage, and ease menopausal symptoms. Critical to this is the accessibility of detailed insights into bodily changes, driving increased demand for at-home tracking solutions. Mira, for instance, launched a Menopause Transitions Kit that allows women to track hormonal shifts over time, helping them identify patterns early and adapt their health strategies proactively.
Accurately predicting the onset of menopause has long been a challenge, but 2025 could mark a change. In 2024, there has been a notable increase in research into early menopause, with scientists focused on developing predictive models to pinpoint when and why menopause is likely to occur. Combined with a growing supply of personal hormonal, genetic, and general health data, predicting and preventing symptoms—and preparing for its impact on family, work, and health—will ease the struggles of aging.
2. Digital biomarker integration
Wearable technology has made accessing vast amounts of digital biomarkers—objective physiological measures collected through digital devices—possible at an affordable price, providing individuals with a clearer picture of their health and well-being.
However, unlocking the full potential of this data will require greater collaboration within the women’s health sector. For instance, research shows that blood glucose levels increase during ovulation and drop sharply during menstruation—which can cause significant physical and emotional impacts. By integrating blood glucose-related biomarkers with menstrual-related data, women could better understand how their cycles impact glucose levels and how they can adjust their treatment plans accordingly.
In the year ahead, the sector will shift toward combining its diverse data sources to create holistic, personalized health solutions. For example, wearable tech firms WHOOP and Withings collaborated, providing users with the tools to measure and manage advanced body composition metrics.
3. AI assistants
AI use will only increase in the year ahead as part of the wider shift towards making services and support more accessible and convenient for women who are 50% more likely to skip appointments due to long wait times. In addition, 9% admit they lack reliable transportation, and 7% state appointments clash with their work schedule.
This trend will also prompt a greater shift towards asynchronous telehealth—enabling patients to share information digitally and doctors to respond when available, providing greater flexibility and improved efficiency for both patients and often understaffed healthcare services.
4. Market consolidation
Much of this innovation will be driven by mergers and acquisitions, as companies seek to consolidate expertise and resources to strengthen their market positions. Such deals are likely to become more frequent as market leaders position themselves for growth and tech giants expand into the space—as shown by Samsung’s recent acquisition of fetal ultrasound company Sonio.
Companies leveraging bio-generated data will be particularly attractive targets as precision health—personalized approaches that take into account a person’s genes, environment, and lifestyle—take center stage in healthcare innovation. For example, Mira partnered with Oura to support women on their menopause journeys by combining Mira’s hormone tracking with Oura’s personalized health insights, enabling women to understand the connections between hormone levels, lifestyle factors, and symptoms.
For consumers, greater consolidation will accelerate the development of impactful solutions, with underserved areas such as menopause care, non-hormonal birth control, and STI treatments particularly well-positioned for breakthroughs.
5. Continued trials and tribulations in femtech
Despite the progress, deep-rooted challenges remain that must be addressed to maintain growth.
A lack of research has historically held women’s health back, with women often still excluded from clinical trials for reasons from ‘hormone interference’ to a lack of fundamental differences between male and female bodies. However, health data tells a very different story. Women are twice as likely to die from heart attacks, worse affected by lung cancer, and more likely to suffer from Alzheimer’s and autoimmune diseases. Evidently, there are fundamental differences that require women-focused research to understand.
While progress is being made—evidenced by the growing investment in femtech—significant funding gaps remain. Women’s health only accounts for less than 2% of total health technology funding. This disparity is not due to a lack of promise or demand, but stems from the male-dominated venture capital landscape, where over 80% of firm partners are men, and—in my experience—do not understand the critical need to improve women’s health.
Compounding the issue, a disproportionate amount of femtech funding is directed toward male-led startups. While men are welcome in the sector, gender biases are undeniably shaping the space. Female-founded femtech startups raise 23% less capital on average and receive just 28% of VC funding—10% less than male-led teams.
Femtech holds significant promise, and 2025 will be another successful year for the sector. However, addressing biases and ensuring fair access to funding will be critical to unlocking its full potential—and finally bringing women’s health up to standards.
About Sylvia Kang
Sylvia Kang is a biomedical engineer and founder of Mira, a San Francisco-based hormonal health company providing integrative care and hormonal testing for over 150,000 customers. Mira’s most important breakthrough was inventing the market’s only FDA-compliant at-home fertility monitor with quantitative technology. Since 2015, Sylvia has been on a mission to develop data-driven hormonal health solutions to help women make confident health decisions during every stage of their lives—from the menstrual stage to menopause.